Melevodopa (hydrochloride)

Melevodopa (Levodopa methylester) hydrochloride is an orally active methylated prodrug of Levodopa (HY-N0304), a dopamine precursor. When used in combination with Carbidopa (HY-B0311) in an effervescent tablet formulation, Melevodopa hydrochloride inhibits motor fluctuations in Parkinson's disease. Melevodopa hydrochloride suppresses subcutaneous tumor growth, pulmonary metastasis proliferation, and primary mass invasiveness of melanoma. Melevodopa hydrochloride induces lipid peroxidation by increasing malondialdehyde levels in melanoma and improves the survival rate of melanoma-bearing mice. Melevodopa hydrochloride can be used in research related to Parkinson's disease (with motor fluctuations) and melanoma^[1][2]. In Vivo:Melevodopa (1000 mg/kg; i.p.; daily; 15 days; preceded by Carbidopa 100 mg/kg 90-minute pre-injection) hydrochloride inhibits subcutaneous B16 melanoma growth and increases median survival by 23% in basal diet-fed mice and 36% in tyrosine/phenylalanine-restricted diet-fed mice, while also reducing tumor invasiveness and increasing tumor lipid peroxidation^[2].
Melevodopa (1000 mg/kg; i.p.; daily; 15 days; preceded by Benserazide (HY-121275) 100 mg/kg 90-minute pre-injection) hydrochloride alters B16-BL6 melanoma lung colony size distribution toward smaller colonies in both basal and tyrosine/phenylalanine-restricted diet-fed mice, but does not change total lung colony count^[2].